Key Takeaways from the Progressive\u00a0Supranuclear Palsy Market Report<\/b><\/p>\n Discover the progressive supranuclear palsy new treatment @ New Treatments for Progressive Supranuclear Palsy<\/a><\/b><\/p>\n Progressive Supranuclear Palsy Market Dynamics<\/b><\/p>\n The progressive supranuclear palsy market dynamics are expected to change in the coming years. The progressive supranuclear palsy market is driven by increasing disease awareness, advancements in diagnostic technologies, and growing research efforts<\/b> to develop disease-modifying therapies. Rising prevalence of neurodegenerative disorders, particularly among the aging population, is further fueling the demand for effective PSP treatment options.<\/p>\n Strategic collaborations<\/b>\u00a0between pharmaceutical companies and research institutions are accelerating drug discovery and clinical trials, while regulatory incentives such as orphan drug designations are encouraging innovation in this rare disease space. Additionally, the growing adoption of advanced imaging techniques and biomarker-based diagnostics<\/b> is enabling early and accurate diagnosis, creating a favorable environment for therapeutic interventions and market growth.<\/p>\n As potential therapies are being investigated for the treatment of progressive supranuclear palsy, it is safe to predict that the treatment space will significantly impact the progressive supranuclear palsy\u00a0market during the forecast period. Moreover, the anticipated introduction of emerging therapies<\/b> with improved efficacy and a further improvement in the diagnosis rate<\/b> are expected to drive the growth of the progressive supranuclear palsy\u00a0market in the 7MM.<\/p>\n However, several factors may impede the growth of the progressive supranuclear palsy\u00a0market. A major challenge is the limited understanding of the disease’s underlying pathophysiology, which complicates the identification of viable therapeutic targets. The small patient population and the rarity of PSP restrict the scope of clinical trials, leading to high costs, longer timelines, and recruitment difficulties.<\/p>\n Additionally, the absence of disease-modifying treatments<\/b> and reliance on symptomatic therapies<\/b> limit market growth, as current treatment options provide only minimal clinical benefit. Regulatory hurdles, stringent approval processes, and a high failure rate<\/b> in late-stage clinical trials further exacerbate the challenges. Moreover, the lack of robust diagnostic tools and biomarkers<\/b> often delays early diagnosis, reducing the potential for timely interventions and effective disease management.<\/p>\n Progressive Supranuclear Palsy Treatment Market<\/b><\/p>\n At present, no approved medications or standardized clinical guidelines exist specifically for the treatment of progressive supranuclear palsy. Management focuses on alleviating symptoms, providing supportive care, and enhancing the patient’s quality of life. Drugs commonly prescribed for Parkinson’s disease, such as levodopa, may offer some relief from motor symptoms like rigidity, tremors, and bradykinesia, but their effectiveness in PSP is generally limited and short-lived. Dopamine agonists, including amantadine and ropinirole, can be used alone or in combination with levodopa, though they provide only modest benefits.<\/p>\n Beyond medications, a multidisciplinary care approach is crucial. Physical therapy aids in improving mobility and balance, occupational therapy assists with daily activities, and speech and swallowing therapy helps manage communication and feeding challenges. These supportive strategies play a key role in preserving the best possible quality of life for PSP patients.<\/p>\n To know more about progressive supranuclear palsy treatment options, visit @ Approved Progressive Supranuclear Palsy Drugs<\/a><\/b><\/p>\n Progressive Supranuclear Palsy Pipeline Therapies and Key Companies<\/b><\/p>\n The emerging pipeline for PSP includes AZP2006 <\/b>(AlzProtect), AMX0035 <\/b>(Amylyx Pharmaceuticals), TPN-101<\/b> (Transposon Therapeutics), FNP-223<\/b> (Ferrer), and others.<\/p>\n AZP2006<\/b>\u00a0is an orally administered small molecule featuring a unique mechanism of action. It acts through a neurotrophic factor, offering enhanced neuroprotective effects combined with anti-inflammatory activity in the nervous system. This compound shows significant therapeutic promise for addressing the underlying pathological mechanisms of progressive supranuclear palsy (PSP) and other tau-related disorders, including Alzheimer’s disease.<\/p>\n In September 2024, the company announced the successful completion of a Phase IIa clinical trial of AZP2006 for PSP treatment. Throughout a 3-month Phase IIa study in PSP patients, the drug demonstrated promising clinical and biomarker efficacy signals. These findings were further corroborated by results from a 6-month open-label extension study, strengthening its therapeutic potential. AZP2006 has also been granted Orphan Drug Designation by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).<\/p>\n In April 2025, the Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF), and Anne-Marie Wills (Massachusetts General Hospital), selected two promising drug candidates, Axon Neuroscience’s AADvac1 and Alzprotect’s AZP2006, as the first compounds to be tested under the platform trial. This initiative aims to accelerate the development of effective treatments for PSP, a rare and fatal neurodegenerative disorder.<\/p>\n AMX0035<\/b>\u00a0is an oral, fixed-dose combination therapy composed of sodium phenylbutyrate and taurursodiol (also known as ursodoxicoltaurine). It has a strong mechanistic rationale for PSP, targeting critical upstream pathways involved in disease pathogenesis, such as the unfolded protein response and mitochondrial dysfunction. Additionally, AMX0035 has been shown to lower p-tau levels in Alzheimer’s disease studies.<\/p>\n Currently, AMX0035 is being evaluated in a global Phase IIb\/III (ORION) clinical trial, which aims to determine its efficacy, safety, and tolerability in PSP patients. The trial is expected to conclude by April 2026, with Amylyx Pharmaceuticals planning to release safety and efficacy data from the unblinded Phase IIb portion of the study in Q3 2025.<\/p>\n The anticipated launch of these emerging therapies are poised to transform the progressive supranuclear palsy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the progressive supranuclear palsy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n Discover more about progressive supranuclear palsy marketed and pipeline drugs\u00a0@ Progressive Supranuclear Palsy Clinical Trials<\/a><\/b><\/p>\n Recent Developments in the Progressive Supranuclear Palsy Market<\/b><\/p>\n Progressive Supranuclear Palsy Overview<\/b><\/p>\n Progressive supranuclear palsy is a rare neurodegenerative disorder that affects movement, balance, speech, and eye movements. It is caused by the accumulation of abnormal tau protein in certain areas of the brain, leading to the degeneration of nerve cells. While the exact cause of PSP is not fully understood, it is believed to involve a combination of genetic and environmental factors. PSP typically affects individuals over the age of 60 and progresses gradually over time.<\/p>\n The symptoms of PSP include difficulties with balance and frequent falls, stiffness and slow movements similar to Parkinson’s disease, and problems with eye movements, particularly the inability to move the eyes up and down. Other symptoms may include speech and swallowing difficulties, personality changes, irritability, depression, and cognitive decline. Unlike Parkinson’s disease, tremors are uncommon in PSP, which helps in differentiating the two conditions.<\/p>\n Diagnosis of PSP is challenging as there is no specific test to confirm the condition. It is primarily diagnosed based on clinical symptoms, neurological examinations, and the exclusion of other similar conditions. Brain imaging techniques, such as MRI, may reveal characteristic brain changes like midbrain shrinkage, which supports the diagnosis. Early recognition of eye movement abnormalities and postural instability is crucial for an accurate diagnosis.<\/p>\n Progressive Supranuclear Palsy Epidemiology Segmentation<\/b><\/p>\n The progressive supranuclear palsy\u00a0epidemiology section provides insights into the historical and current progressive supranuclear palsy\u00a0patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n The progressive supranuclear palsy\u00a0market report\u00a0proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM, segmented into:<\/p>\n Progressive Supranuclear Palsy Market Report Metrics<\/b><\/p>\n<\/td>\n Details<\/b><\/p>\n<\/td>\n<\/tr>\n Study Period<\/p>\n<\/td>\n 2020\u20132034<\/p>\n<\/td>\n<\/tr>\n Coverage<\/p>\n<\/td>\n 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].<\/p>\n<\/td>\n<\/tr>\n Key Progressive Supranuclear Palsy Companies<\/p>\n<\/td>\n Amylyx Pharmaceuticals, AlzProtect, Transposon Therapeutics, Ferrer, Asceneuron, UCB Biopharma, Novartis, and others<\/p>\n<\/td>\n<\/tr>\n Key Progressive Supranuclear Palsy Therapies<\/p>\n<\/td>\n AMX0035, AZP2006, TPN-101, FNP-223\/ASN90, Bepranemab (UCB0107), NIO752, and others<\/p>\n<\/td>\n<\/tr>\n Scope of the <\/b>Progressive Supranuclear Palsy<\/b>\u00a0Market Report<\/b><\/p>\n Download the report to understand which factors are driving progressive supranuclear palsy therapeutics market\u00a0trends\u00a0@\u00a0Progressive Supranuclear Palsy Market Trends<\/a><\/b><\/p>\n Table of Contents<\/b><\/p>\n 1.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Market Key Insights<\/p>\n<\/td>\n<\/tr>\n 2.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Market Report Introduction<\/p>\n<\/td>\n<\/tr>\n 3.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n 4.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Market Executive Summary<\/p>\n<\/td>\n<\/tr>\n 5.<\/p>\n<\/td>\n Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n 6.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Treatment and Management<\/p>\n<\/td>\n<\/tr>\n 7.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n 8.<\/p>\n<\/td>\n Patient Journey<\/p>\n<\/td>\n<\/tr>\n 9.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Marketed Drugs<\/p>\n<\/td>\n<\/tr>\n 10.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n 11.<\/p>\n<\/td>\n Seven Major Progressive Supranuclear Palsy Market Analysis<\/p>\n<\/td>\n<\/tr>\n 12.<\/p>\n<\/td>\n Progressive Supranuclear Palsy Market Outlook<\/p>\n<\/td>\n<\/tr>\n 13.<\/p>\n<\/td>\n Potential of Current and Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n 14.<\/p>\n<\/td>\n KOL Views<\/p>\n<\/td>\n<\/tr>\n 15.<\/p>\n<\/td>\n Unmet Needs<\/p>\n<\/td>\n<\/tr>\n 16.<\/p>\n<\/td>\n SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n Related Reports<\/b><\/p>\n Progressive Supranuclear Palsy Pipeline<\/a><\/b><\/p>\n Progressive Supranuclear Palsy\u00a0Pipeline Insight \u2013\u00a02025<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PSP companies, including\u00a0Amylyx Pharmaceuticals, Transposon Therapeutics, Inc., Ferrer International, Novartis Pharmaceuticals, TauC3 Biologics, <\/b>among others.<\/p>\n Parkinson’s Disease Market<\/a><\/b><\/p>\n Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, LLC,<\/b> among others.<\/p>\n Alzheimer’s Disease Market<\/a><\/b><\/p>\n Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast <\/b>\u2013 2034 <\/b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer’s disease companies including AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol-Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC,<\/b> among others.<\/p>\n Dementia Market<\/a><\/b><\/p>\n Dementia Market Insights, Epidemiology, and Market Forecast <\/b>\u2013 2034 <\/b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies including Eisai Co., Ltd., Eli Lilly and Company, Novartis AG, DAIICHI SANKYO COMPANY, LIMITED, AbbVie Inc., Lundbeck, Biogen, Cipla,<\/b> among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Contact Us\n
\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<\/b>Shruti Thakur
[email\u00a0protected]<\/a>
+14699457679
www.delveinsight.com<\/a><\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO46394&Transmission_Id=202508071731PR_NEWS_USPR_____IO46394&DateId=20250807\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The progressive supranuclear palsy market is expected to witness steady growth due to increasing disease awareness, advancements in…\n","protected":false},"author":3,"featured_media":28217,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,24334,4629,135,67,132,68],"class_list":{"0":"post-127478","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-llp","11":"tag-markets","12":"tag-united-states","13":"tag-unitedstates","14":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114989873604105447","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/127478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=127478"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/127478\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/28217"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=127478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=127478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=127478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}